Summary

Objectives

Eligibility

1. ELIGIBILITY CRITERIA FOR SCREENING BIOPSY (STEP 0)
2. Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration; patients that are pregnant or breast feeding are excluded; a patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: * Has achieved menarche at some point * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
3. Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse prior to study entry, for the duration of study participation, and for 4 months after completion of study; should a patient or partner of the patient become pregnant or suspect a pregnancy while participating in this study, the treating physician should be informed immediately
4. Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and meet one of the following criteria: * Patients must have progressed following at least one line of standard systemic therapy and there must not be other approval/standard therapy available that has been shown to prolong overall survival (i.e. in a randomized trial against another standard treatment or by comparison to historical controls); patients who cannot receive other standard therapy that has been shown to prolong overall survival due to medical issues will be eligible, if other eligibility criteria are met; if the patient is currently receiving therapy, the clinician must have assessed that the current therapy is no longer benefitting the patient prior to enrolling on MATCH, regardless of whether it is considered standard OR * Patients for whose disease no standard treatment exists that has been shown to prolong overall survival * NOTE: No other prior malignancy is allowed except for the following: * Adequately treated basal cell or squamous cell skin cancer * In situ cervical cancer * Adequately treated stage I or II cancer from which the patient is currently in complete remission * Any other cancer from which the patient has been disease-free for 5 years
5. Patients must have measurable disease
6. Patients must meet the criteria below * Tumor tissue for the confirmation of “rare variant” by the MATCH assay is to be submitted, preferably from the same time of collection as that used to determine patient candidacy for treatment arm assignment ** Registration to Step 0 must occur after stopping prior systemic anti-cancer therapy. There is no specific duration for which patients must be off treatment prior to registration to Step 0, as long as all eligibility criteria are met ** Patients may have received other non-targeted, immunotherapy or targeted treatment between the prior genetic testing at the outside lab and registration to Step 0. The decision to stop such treatment in favor of participation in MATCH, if no further clinical benefit is expected, is per the treating physician's discretion. Documentation of a lack of response to the prior treatment is not required in these cases ** Patients with an applicable “rare variant” must be able to meet the eligibility criteria for the appropriate subprotocols within 4 weeks following notification of treatment assignment ** Patient meets one of the following criteria: *** Patient is a candidate for Z1M based on local CLIA assessment of MMRd by immunohistochemistry (IHC) or MSI status by polymerase chain reaction (PCR), adequate tumor tissue is available for submission for mandatory central screening IHC and the patient will be able to meet the eligibility criteria for Z1M within 4 weeks following notification of treatment assignment OR *** The sites have received results from one of the designated outside laboratories indicating a “rare variant” that is an actionable Mutation of Interest (aMOI) for specific select subprotocols * NOTE: There is no particular window of time after receiving the sequencing report notification of potential eligibility from an outside lab in which the patient must be registered to Step 0, but treatment slots will be assigned on a first come, first serve basis to those who do register to Step 0, and are not held for those notified of potential eligibility who do not register to Step 0 * NOTE: Treatment assignment (and the start of the associated deadline for Step 1 registration) may occur shortly after Step 0 registration. Note that certain “rare variant” arms require submission of archival tissue for central IHC testing to determine treatment assignment. For those arms, adequate tissue for the central IHC is required to be available for submission * NOTE: Other potential aMOIs that would be eligibility criteria for “NON RARE” arms, as determined by the designated laboratories, are not applicable for this process in MATCH
7. Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 and a life expectancy of at least 3 months
8. Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible
9. Patients who are human immunodeficiency virus (HIV)-positive are eligible if: * CD4+ cell count greater or equal to 250 cells/mm^3 * If patient is on antiretroviral therapy, there must be minimal interactions or overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment; for experimental cancer therapeutics with CYP3A/4 interactions, protease inhibitor therapy is disallowed; suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used * No history of non-malignancy acquired immune deficiency syndrome (AIDS)-defining conditions other than historical low CD4+ cell counts * Probable long-term survival with HIV if cancer were not present
10. Any prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed >= 4 weeks prior to start of treatment; all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment; palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment; the radiotherapy must not be to a lesion that is included as measurable disease * NOTE: Prostate cancer patients may continue their luteinizing hormone-releasing hormone (LHRH) agonist * NOTE: For patients entering the study via the original screening process, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results; however, lack of response must be documented prior to registration to Step 1; new non-protocol treatment will NOT be permitted as intervening therapy after registration to Step 0; the only intervening treatment permitted is prior therapy that the patient already received prior to Step 0 registration; the decision to stop the intervening non-protocol treatment will be left up to the treating physician if patient has an aMOI; however, patients will need to be off such therapy for at least 4 weeks before receiving any MATCH protocol treatment * NOTE: For patients entering the study via a designated outside laboratory, no intervening systemic non-protocol treatment is permitted after Step 0 registration; all other eligibility requirements still apply to these patients, including the washouts for prior therapy noted above in this section, the time restrictions outlined, and the eligibility criteria for the intended subprotocol
11. Patients with brain metastases or primary brain tumors must have completed treatment, surgery or radiation therapy >= 4 weeks prior to start of treatment
12. Patients must have discontinued steroids >= 1 week prior to registration to Step 0 and remain off steroids thereafter, except as permitted; patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to treatment (Step 1, 3, 5, 7) * NOTE: The following steroids are permitted (low dose steroid use is defined as prednisone 10 mg daily or less, or bioequivalent dose of other corticosteroid): ** Temporary steroid use: e.g. for computed tomography (CT) imaging in setting of contrast allergy ** Low dose steroid use for appetite ** Chronic inhaled steroid use ** Steroid injections for joint disease ** Stable dose of replacement steroid for adrenal insufficiency or low doses for non-malignant disease ** Topical steroid ** Steroids required to manage toxicity related to study treatment, as described in the subprotocols ** Steroids required as pre- or post-chemotherapy medication for acceptable intervening chemotherapy *** NOTE: Steroids must be completed alongside last dose of chemotherapy
13. Leukocytes >= 3,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
14. Absolute neutrophil count (ANC) >= 1,500/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
15. Platelets >= 100,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
16. NOTE: Patients with documented bone marrow involvement by lymphoma are not required to meet the above hematologic parameters, but must have a platelet count of at least 75,000/mcL and neutrophil count of at least 1,000/mcL
17. Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (unless documented Gilbert’s syndrome, for which bilirubin =< 3 x institutional ULN is permitted) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
18. Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (up to 5 times ULN in presence of liver metastases) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
19. Creatinine clearance >= 45 mL/min/1.73 m^2 for patients with creatinine levels above institutional ULN * As defined by the Cockcroft-Gault equation (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)
20. Patients must have an electrocardiogram (ECG) within 8 weeks prior to registration to screening step and must meet the following cardiac criteria: * Resting corrected QT interval (QTc) =< 480 msec ** NOTE: If the first recorded QTc exceeds 480 msec, two additional, consecutive ECGs are required and must result in a mean resting QTc =< 480 msec; it is recommended that there are 10-minute (+/- 5 minutes) breaks between the ECGs * The following only need to be assessed if the mean QTc > 480 msec ** Check potassium and magnesium serum levels ** Correct any identified hypokalemia and/or hypomagnesemia and may repeat ECG to confirm exclusion of patient due to QTc ** For patients with heart rate (HR) 60-100 beats per minute (bpm), no manual read of QTc is required ** For patients with baseline HR < 60 or > 100 bpm, manual read of QT by trained personnel is required, with Fridericia correction applied to determine QTc ** Patient must not have hypokalemia (value < institutional lower limit of normal) * No factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval ** NOTE: Patient must be taken off prohibited medication prior to registration to the screening step (Step 0, 2, 4, 6) and remain off these medications thereafter, unless permitted on a subprotocol for the management of treatment related toxicity; patient must be off the drug for at least 5 half-lives prior to registration to the treatment step (Step 1, 3, 5, 7); the medication half-life can be found in the package insert for Food and Drug Administration (FDA) approved drugs
21. ELIGIBILITY CRITERIA FOR FIRST TREATMENT (STEP 1)
22. NOTE: For patients entering step 0 with assay results from outside laboratories, no systemic treatment is allowed after step 0 registration
23. As MATCH is designed to add additional subprotocols, implement limited expansions of accrual for certain subprotocols, and/or amend existing arm-specific eligibility criteria, some patients entering under the original screening method may be eligible to have their results rerun in MATCHbox, even if they did not match to a treatment initially or did not receive a treatment assignment due to a lack of available assignment slots; patients whose sequence results will be rerun through MATCHbox must also meet the following criteria: * Samples must have been collected within 5 months of the activation of the addendum, as there is an additional month needed to get the patients on trial * Patient has not had treatment within the 5 months that resulted in a PR or better after the performance of the screening assessment * Patient must meet eligibility criteria, including performance status 1 or better and life expectancy of at least 3 months * Patients must meet the eligibility requirements with the following exceptions: ** Patients may have received other non-targeted, immunotherapy or targeted treatment, which could be stopped in favor of returning to MATCH, if no response to the interim treatment has occurred and no further benefit is expected from this interim treatment, per the treating physician's discretion; documentation of a lack of response to the interim treatment is not required in these cases; however, the following restrictions apply: *** Enrollment onto another investigational therapeutic study is not permitted *** Patient cannot be responding to interim treatment, since the benefit of the MATCH treatment is unknown and may deprive patient of an effective treatment if it were given when a patient is responding to another treatment * NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their step 0 results will be re-interrogated to determine if another treatment is available
24. ELIGIBILITY CRITERIA FOR SECOND SCREENING (STEP 2)
25. Patient’s disease has progressed on Step 1 treatment or patient could not tolerate assigned treatment * NOTE: PATIENTS ENTERING STEP 1 WITH A “RARE VARIANT” FROM AN “OUTSIDE” LAB ARE NOT ELIGIBLE FOR STEP 2
26. No response and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 1 treatment * NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their step 0 MATCH assay results will be re-interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance; only aMOIs detected by the MATCH assay may be used for the determination of eligibility to a relevant subprotocol OR
27. Progression (or inability to tolerate further treatment) occurred after a (1) response OR (2) after >= 6 months from start of step 1 treatment; patient must have tumor amenable to percutaneous biopsy and be willing and able to undergo a tumor biopsy or bone marrow aspirate for collection and submission of tumor tissue OR patient will be undergoing a procedure due to medical necessity during which the tissue may be collected for the central determination of the presence of one or more of the specific “actionable” mutations/amplifications of interest (aMOI); archived specimens cannot be accepted
28. Patients must meet eligibility criteria as defined in step 0
29. ELIGIBILITY CRITERIA FOR SECOND TREATMENT (STEP 3)
30. NOTE: If screening biopsy samples were submitted during step 2, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results however, lack of response must be documented prior to registration to step 3; new non-protocol treatment will NOT be permitted as intervening therapy after registration to step 2; the decision to stop the intervening nonprotocol treatment will be left up to the treating physician if patient has an aMOI; waiting periods as described will apply
31. ELIGIBILITY CRITERIA FOR THIRD SCREENING (STEP 4)
32. Patient’s disease has progressed on step 3 treatment or patient could not tolerate assigned treatment * Patient must meet one of the following criteria: ** No response and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 3 (second) treatment AND a biopsy was performed at step 2 screening *** NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, their latest MATCH assay results will be re-interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance OR ** Progression (or inability to tolerate further treatment) occurred on step 3 treatment and a biopsy was not performed at step 2 screening (due to presence of additional aMOIs at that stage); patient must have tumor amenable to percutaneous biopsy and be willing and able to undergo a tumor biopsy or bone marrow aspiration for collection and submission of tumor tissue OR patient will be undergoing a procedure due to medical necessity during which the tissue may be collected for the central determination of the presence of one or more of the specific “actionable” mutations/amplifications of interest; biopsy must not be considered to be more than minimal risk to the patient; archived specimens cannot be accepted
33. Patients must meet eligibility criteria as defined in step 0 * NOTE: A patient may have a maximum of 2 screening biopsies (not including re-biopsy due to assay failure), and 2 MATCH treatments per biopsy (if > 1 aMOI)
34. ELIGIBILITY CRITERIA FOR THIRD TREATMENT (STEP 5)
35. NOTE: If screening biopsy was submitted on step 4, patients may receive non-protocol treatment after biopsy (if clinically indicated) until they receive notification of results however, lack of response must be documented prior to registration to step 5; new non-protocol treatment will NOT be permitted as intervening therapy after registration to step 4; the therapy cannot be an arm in the MATCH trial; the decision to stop the intervening nonprotocol treatment will be left up to the treating physician if patient has an aMOI; waiting periods as described will apply
36. ELIGIBILITY CRITERIA FOR FOURTH SCREENING (STEP 6)
37. Patient’s disease has progressed on step 5 protocol treatment or patient could not tolerate assigned treatment
38. Patient must have had no response, and progression (or inability to tolerate further treatment) occurred < 6 months from start of step 5 treatment AND a biopsy was performed at step 4 screening *NOTE: Patients meeting these criteria will NOT be biopsied at this time point; instead, based on their 2nd biopsy, their results will be interrogated to determine if another treatment is available upon registration to this study step; it is not necessary to confirm the availability of another potential treatment assignment in advance
39. Patients must meet eligibility criteria as defined in step 0 * NOTE: For Step 6, biopsies to collect material for screening assay will NOT be performed; a patient may have a maximum of 2 successful screening assessments of submitted tissue (steps 0 and 2 OR steps 0 and 4), and 2 MATCH treatments per biopsy (if > 1 aMOI)
40. ELIGIBILITY FOR FOURTH TREATMENT (STEP 7)
41. Eligibility requirements for registration onto step 7 are outlined in the agent-specific subprotocol
42. ELIGIBILITY CRITERIA FOR RESEARCH BIOPSY AND CIRCULATING TUMOR DNA COLLECTION (STEP 8)
43. ALL PATIENTS SHOULD BE ENCOURAGED TO PARTICIPATE IN STEP 8, IF SAFE; IF BIOPSY IS REFUSED OR INADVISABLE, ENCOURAGE COLLECTION OF WHOLE BLOOD FOR CIRCULATING TUMOR DNA As a reminder, the submission of the step 8 samples requires additional patient consent, as well as registration to step 8 * NOTE: Patients who entered the study (step 0) with a “rare variant” determined by an outside assay ARE potentially eligible and encouraged to participate in step 8
44. Patient has completed their most recent MATCH study treatment, will not undergo an additional screening biopsies, and will receive no additional treatment on MATCH * NOTE: If a 2nd Screening Biopsy was performed and showed no study-actionable abnormalities, and blood samples were submitted with the screening biopsy, no additional end of treatment specimens are requested
45. For patients who consent to undergo the optional research biopsy, patient’s disease responded to the most recent MATCH study treatment and then progressed (or unable to tolerate further treatment) OR the disease progression (or inability to tolerate further treatment) occurs > 6 months since the last screening biopsy * NOTE: Performance of a biopsy to collect tumor tissue for research is strongly encouraged but not required; it is acceptable to submit only the optional blood specimens * NOTE: If a biopsy will be performed solely to collect tumor specimens for research, the patient must be willing and able to undergo a tumor biopsy or bone marrow aspirate (for applicable multiple myeloma), for the collection and submission of tissue for research

Treatment Sites in Georgia

Atlanta Cancer Care - Alpharetta

3400 C Old Milton Parkway
Suite 400
Alpharetta, GA 30005
770-777-1315
www.atlantacancercare.com

Doctors:

Colleen S. Austin MD
Silpa C. Reddy MD
Sreekanth C. Reddy MD
Ronald G. Steis MD

Atlanta Cancer Care - Conyers

1498 Klondike Road
Suite 106
Conyers, GA 30094
404-303-3355
www.atlantacancercare.com

Doctors:

Richard A. Carter MD

Atlanta Cancer Care - Cumming

1505 Northside Boulevard
Suite 4600
Cumming, GA 30041
770-205-5292 x1041
www.atlantacancercare.com

Doctors:

Sreekanth C. Reddy MD
Ronald G. Steis MD
Amelia B. Zelnak MD
Kelly A. May MD

Atlanta Cancer Care - Decatur

2545 Lawrenceville Highway
Suite 300
Decatur, GA 30033
404-303-3355
www.atlantacancercare.com

Doctors:

Lijo Simpson MD

Atlanta Cancer Care - Stockbridge

7813 Spivey Station Boulevard
Suite 210
Jonesboro, GA 30236
678 466-2069
www.atlantacancercare.com

Doctors:

Gurinderjit K. Sidhu MD
Lijo Simpson MD

Atlanta Cancer Care - Tower

5670 Peachtree Dunwoody Road
Suite 1100
Atlanta, GA 30342
404-303-3355
www.atlantacancercare.com

Doctors:

Colleen S. Austin MD
Silpa C. Reddy MD
Sreekanth C. Reddy MD
Kelly A. May MD

Atlanta Gynecologic Oncology

980 Johnson Ferry Road
Suite 900
Atlanta, GA 30342
404-303-3355
www.geraldfeuer.com

Doctors:

Gerald A. Feuer MD

Atrium Health Navicent

Oncology Research, Atrium Health Navicent
777 Hemlock Street, MSC 123
(PACC 800 1st St, Ste 250)
Macon, GA 31201
4786332152
www.Atriumhealth.org

Study Coordinator:
Oncology Research Nurse
4786332152

Doctors:

Linda K. Hendricks MD
Bradley T. Sumrall MD
Harry F. Moore, Jr. MD

Augusta University Medical Center

1120 15th Street
Augusta, GA 30912
706-721-4430
www.augustahealth.org

Cancer Center at DeKalb Medical Center

2675 North Decatur Road
Suite 410
Decatur, GA 30033
404-501-7789
www.dekalbmedical.org

Doctors:

Cyril O. Spann MD,SM, FACOG, FACS
Jayanthi Srinivasiah MD

City of Hope Atlanta

600 Celebrate Life Parkway
Newnan, GA 30265
www.cancercenter.com

Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center

4700 Waters Avenue
Savannah, GA 31404
912-350-8913
www.memorialhealth.com/anderson-cancer-institute.aspx

Emory Saint Joseph's Hospital

5665 Peachtree Dunwoody Road NE
Atlanta, GA 30342
www.emoryhealthcare.org

Emory University Hospital - Midtown

550 Peachtree Street NE
Atlanta, GA 30308
404-686-4411
www.emoryhealthcare.org

Georgia Cancer Specialists - Athens

125 King Avenue
Suite 200
Athens, GA 30606
www.gacancer.com

Doctors:

Ranjana S. Bhargava MD
Priya Rudolph

Georgia Cancer Specialists - Canton

228 Riverstone Drive
Canton, GA 30114
www.gacancer.com

Doctors:

Louis Crain Garrot MD
Gena H. Volas-Redd MD
Lynn M. Zemsky MD

Georgia Cancer Specialists - CenterPointe

1100 Johnson Ferry Road
Suite 600
Sandy Springs, GA 30342
404-256-4777 ext 9242
www.gacancer.com

Doctors:

Rodolfo E. Bordoni MD
Pradeep C. Jolly MD

Georgia Cancer Specialists - Kennestone

790 Church Street
Suite 335
Marietta, GA 30060
www.gacancer.com

Doctors:

Louis Crain Garrot MD
Gena H. Volas-Redd MD
Lynn M. Zemsky MD

Georgia Cancer Specialists - Macon-Coliseum

308 Coliseum Drive
Suite 120
Macon, GA 31217
478-745-6130 x8152
www.gacancer.com

Doctors:

Cheryl F. Jones MD
Premila Malhotra MD

Georgia Cancer Specialists - Stemmer

2712 Lawrenceville Highway
Decatur, GA 30033
770-496-5555
www.gacancer.com

Doctors:

Jayanthi Srinivasiah MD
Simbo O. Aduloju MD
Aaron R. Alizadeh MD
Kathleen E. Lambert MD

Harbin Clinic Cancer Center

255 West Fifth Street
Rome, GA 30165
706-528-9110
www.harbinclinic.com

Study Coordinator:
Terri Brannon
706-528-9094

Doctors:

Dilawar Khan MD

Northeast Georgia Medical Center - Gainesville

NGMC-Gainesville
Wisteria Building Suite 420
200 South Enota
Gainesville, GA 30501
770-219-8822
www.nghs.com

Study Coordinator:
Trena Davis BSN, RN, CRCC
770-219-8822

Northside Hospital Cancer Institute

1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

Study Coordinator:
404-303-3355

Doctors:

Gerald A. Feuer MD
Louis Crain Garrot MD
Pradeep C. Jolly MD
Cheryl F. Jones MD
Jayanthi Srinivasiah MD
Gena H. Volas-Redd MD
Amelia B. Zelnak MD
Simbo O. Aduloju MD
Premila Malhotra MD
Aaron R. Alizadeh MD
Guilherme Cantuaria MD
Kelly A. May MD
Ranjana S. Bhargava MD
Priya Rudolph
Kathleen E. Lambert MD

Pearlman Cancer Center at South Georgia Medical Center

2501 North Patterson Street
Valdosta, GA 31602
229-259-4628
www.sgmc.org

Piedmont Columbus Regional

1831 5th Ave
Columbus, GA 31901
www.columbusregional.com

Study Coordinator:
Jay Pitts, BS, CPhT
706-596-5426

Doctors:

Wilbur B. Bassett, Jr. MD
Andrew W. Pippas MD
Peter Q. Jiang MD
Suresh Nukala MD

University Gynecologic Oncology

960 Johnson Ferry Road
Suite 130
Atlanta, GA 30342
404-303-3355
www.ugynonc.com

Doctors:

Oi Stephanie Yap MD, FACOG
Guilherme Cantuaria MD
Benedict B. Benigno MD
Meaghan Tenney MD

Winship Cancer Institute of Emory University

1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu